Explaining Jolie's cancer:
News of Angelina Jolie's decision
to undergo a prophylactic double mastectomy has instantly increased awareness
of hereditary forms of cancer caused by mutations in the BRCA1 and BRCA2 genes.
Fig. Actress Angelina Jolie |
While the BRCA1 and BRCA2 genes
were discovered in the mid-1990s, genetic testing for the genes is increasingly
available. Jolie's case highlights the importance of knowing one's family
history and learning one's cancer risks in order to address them proactively.
Everyone has the BRCA1 and BRCA2
genes. We have two copies of each gene and get one each from our mother and
father. They play a role in protecting the body against the development of
cancer.
Individuals with mutations in
either of these genes have increased cancer risks, most notably for breast and
ovarian cancer. Individuals with mutations in BRCA1 and BRCA2 benefit from
tailored management aimed at reducing cancer risks and detecting cancers early
when they are most treatable.
Genetic counselors and other
health care providers can help determine if testing is appropriate and who in
the family should undergo testing first. In addition, it is important to
provide educational and anticipatory guidance on the impact and implications of
genetic test results.
Here are some common questions regarding
genetic testing for breast and ovarian cancer:
What is BRCA testing?
BRCA testing is a genetic test
that looks at the sequence or code of the BRCA1 and/or BRCA2 genes. Changes or
mutations in the genetic code indicate increased cancer risks. The test can be
performed on a blood or saliva sample. It takes about three weeks to get
results.
What does a positive result mean?
A positive test result in BRCA1
or BRCA2 means that the person has a genetic mutation that increases cancer
risk. A positive BRCA1 result gives a woman a 60% to 80% lifetime risk of
breast cancer and a 30% to 45% lifetime risk of ovarian cancer. A positive
BRCA2 result gives a woman a 50% to 70% lifetime risk of breast cancer and a
10% to 20% lifetime risk of ovarian cancer.
Opinion: When removing breast is
not the answer
BRCA1 and BRCA2 are also
associated with other moderately increased cancer risks that vary, depending on
which gene has a mutation. For example, BRCA2 mutations are also associated
with an increased risk of prostate cancer, pancreatic cancer and male breast
cancer.
Does everyone need to be tested?
If not, who should be?
Only about 5% of breast cancers
and 10% to 15% of ovarian cancers are caused by mutations in BRCA1 and BRCA2.
Therefore, not everyone needs to undergo genetic testing.
Genetic counselors and other
health care providers can help determine whether genetic testing is appropriate
by exploring one's personal and family history of cancer and other factors such
as ethnicity, as BRCA1 and BRCA2 mutations are more common in certain
populations.
How much is BRCA testing, and
does insurance cover it?
BRCA testing is usually covered
by insurance if certain criteria are met. There are different types of BRCA
testing, ranging in cost from $475 to about $4,000. Genetic counselors are
helpful in determining what type of testing is indicated. Testing is less
expensive once a mutation has been identified within a family.
Who should get genetic
counseling?
Individuals with a personal or
family history of breast cancer appearing before age 50, ovarian cancer at any
age, breast cancer in both breasts, male breast cancer, multiple cases of
breast cancer within a family, and breast cancer in individuals of Ashkenazi
Jewish ancestry should get genetic counseling to determine whether they should
be tested.
When should I be tested ?
In addition to determining if
BRCA testing is appropriate for you or your family, your health care providers
can help you consider when to undergo genetic testing.
Why more women are choosing
double mastectomies:
It is important to consider when
medical management might be changed for individuals with BRCA1 or BRCA2
mutations, as this can guide the decision of when to test. For example, breast
cancer screening typically starts at age 25 for women with mutations. Since
BRCA mutations are not associated with pediatric cancer risks, testing for
children is not recommended.
Fig. Angelina Jolie and Bradd pitt with family |
What factors should I weigh in
deciding whether to have a preventive mastectomy or oophorectomy (ovary
removal)?
Detailed discussions with
genetics experts, surgical oncologists, plastic surgeons and genetic counselors
are important steps in considering whether and when a prophylactic mastectomy
or oophorectomy is right for you.
While the lifetime risk for
breast and ovarian cancers in BRCA carriers are high, the risks increase with
age. Considering the risk of breast or ovarian cancer based on age can be
helpful in timing these interventions.
Since breast cancer screening is
good at picking up breast cancers early, when they are most treatable,
screening is a reasonable option for carriers. Since ovarian cancer screening
has not been proven reliably to catch ovarian cancers early, risk-reducing
oophorectomy is recommended for BRCA1 and BRCA2 carriers, ideally between the
ages of 35 and 40.
(Source: Dr. Susan Domchek, Special to CNN)
Dr. Susan Domchek is a
board-certified medical oncologist at the University of Pennsylvania's Abramson
Cancer Center. She is director of the Mariann and Robert MacDonald Women's
Cancer Risk Evaluation Center and executive director of the Basser Research
Center for BRCA, a newly founded center focused exclusively on issues related
to BRCA1 and BRCA2 gene mutations.
No comments:
Post a Comment